Company intelligence / Profile preview

1E Therapeutics

Rehovot, Israelfinder.startupnationcentral.org ↗

Ownership: Private
Employees: ~125
Development stage: Preclinical

Overview

The company has developed a DNAzyme that can distinguish between two RNA strands inside a cell and cut the disease-associated strand. They have lead compounds addressing various indications but appear to be in early development stages.

Therapeutic areas: ImmunologyOtherOncologyNeurologyInfectious Diseases
Modalities: RNA-targeting therapeuticsDNA enzyme (DNAzyme)
Industry: Biotech

Beyond the preview

Go deeper on 1E Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 1E Therapeutics.

Explore the full profile